PerkinElmer & Predictive Diagnostics find Alzheimer's biomarkers:
This article was originally published in Clinica
PerkinElmer and Predictive Diagnostics, under a research collaboration, have discovered biomarkers in blood for Alzheimer's Disease. The companies analysed blood using PerkinElmer's BioXPRESSION biomarker platform and Predictive Diagnostic's BAMF technology to identify patterns of proteins and peptides that distinguished Alzheimer's disease patients from those without clinical signs of the condition. Predictive Diagnostics' parent company, Vacaville, California-based Large Scale Biology, noted, however, that the results still needed to be replicated in a separate study. The findings were presented on April 14, at the American Association of Clinical Chemistry's Oak Ridge conference in Baltimore, Maryland.
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”